Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

255 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Correction to: Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population.
De Laurentiis M, Borstnar S, Campone M, Warner E, Bofill JS, Jacot W, Dent S, Martin M, Ring A, Cottu P, Lu J, Ciruelos E, Azim HA, Chatterjee S, Zhou K, Wu J, Menon-Singh L, Zamagni C. De Laurentiis M, et al. Breast Cancer Res Treat. 2022 Jan;191(1):223-224. doi: 10.1007/s10549-021-06374-6. Breast Cancer Res Treat. 2022. PMID: 34625861 Free PMC article. No abstract available.
Demographic, tumor and clinical features of clinical trials versus clinical practice patients with HER2-positive early breast cancer: results of a prospective study.
Arpino G, Michelotti A, Truini M, Montemurro F, Russo S, Palumbo R, Zamagni C, Latorre A, Bruzzese D, Riccardi F, De Laurentiis M, Beano A, Biganzoli L, Zaniboni A, Laudadio L, Malagoli M, Bilancia D, Schettini F, Giuliano M, Cazzaniga ME, De Placido S. Arpino G, et al. Among authors: de placido s, de laurentiis m. J Cancer Res Clin Oncol. 2016 Mar;142(3):669-78. doi: 10.1007/s00432-015-2033-z. Epub 2015 Aug 25. J Cancer Res Clin Oncol. 2016. PMID: 26531187
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.
von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber RD, Piccart M, Baselga J; APHINITY Steering Committee and Investigators. von Minckwitz G, et al. N Engl J Med. 2017 Jul 13;377(2):122-131. doi: 10.1056/NEJMoa1703643. Epub 2017 Jun 5. N Engl J Med. 2017. PMID: 28581356 Free PMC article. Clinical Trial.
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients.
Gligorov J, Ataseven B, Verrill M, De Laurentiis M, Jung KH, Azim HA, Al-Sakaff N, Lauer S, Shing M, Pivot X; SafeHer Study Group. Gligorov J, et al. Among authors: de laurentiis m. Eur J Cancer. 2017 Sep;82:237-246. doi: 10.1016/j.ejca.2017.05.010. Epub 2017 Jun 16. Eur J Cancer. 2017. PMID: 28625777 Clinical Trial.
Adjuvant Subcutaneous Trastuzumab for HER2-Positive Early Breast Cancer: Subgroup Analyses of Safety and Active Medical Conditions by Body Weight in the SafeHer Phase III Study.
Jung KH, Ataseven B, Verrill M, Pivot X, De Laurentiis M, Al-Sakaff N, Lauer S, Shing M, Gligorov J, Azim HA. Jung KH, et al. Among authors: de laurentiis m. Oncologist. 2018 Oct;23(10):1137-1143. doi: 10.1634/theoncologist.2018-0065. Epub 2018 Jul 17. Oncologist. 2018. PMID: 30018134 Free PMC article. Clinical Trial.
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer.
Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, Petrakova K, Bianchi GV, Esteva FJ, Martín M, Nusch A, Sonke GS, De la Cruz-Merino L, Beck JT, Pivot X, Sondhi M, Wang Y, Chakravartty A, Rodriguez-Lorenc K, Taran T, Jerusalem G. Slamon DJ, et al. Among authors: de la cruz merino l, de laurentiis m. N Engl J Med. 2020 Feb 6;382(6):514-524. doi: 10.1056/NEJMoa1911149. Epub 2019 Dec 11. N Engl J Med. 2020. PMID: 31826360 Free article. Clinical Trial.
Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial.
Dent S, Cortés J, Im YH, Diéras V, Harbeck N, Krop IE, Wilson TR, Cui N, Schimmoller F, Hsu JY, He J, De Laurentiis M, Sousa S, Drullinsky P, Jacot W. Dent S, et al. Among authors: de laurentiis m. Ann Oncol. 2021 Feb;32(2):197-207. doi: 10.1016/j.annonc.2020.10.596. Epub 2020 Nov 10. Ann Oncol. 2021. PMID: 33186740 Free PMC article. Clinical Trial.
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival.
Slamon DJ, Neven P, Chia S, Jerusalem G, De Laurentiis M, Im S, Petrakova K, Valeria Bianchi G, Martín M, Nusch A, Sonke GS, De la Cruz-Merino L, Beck JT, Ji Y, Wang C, Deore U, Chakravartty A, Zarate JP, Taran T, Fasching PA. Slamon DJ, et al. Among authors: de la cruz merino l, de laurentiis m. Ann Oncol. 2021 Aug;32(8):1015-1024. doi: 10.1016/j.annonc.2021.05.353. Epub 2021 Jun 5. Ann Oncol. 2021. PMID: 34102253 Free article. Clinical Trial.
Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer.
Dent R, Oliveira M, Isakoff SJ, Im SA, Espié M, Blau S, Tan AR, Saura C, Wongchenko MJ, Xu N, Bradley D, Reilly SJ, Mani A, Kim SB; LOTUS investigators. Dent R, et al. Breast Cancer Res Treat. 2021 Sep;189(2):377-386. doi: 10.1007/s10549-021-06143-5. Epub 2021 Jul 15. Breast Cancer Res Treat. 2021. PMID: 34264439 Clinical Trial.
255 results